-- In the vibrant field of biopharmaceutical innovation, there is always something on the horizon. The Creative Biolabs team showcased a new series of updates in antibody discovery, production, and optimization and was prepared to continue discussions on hot topics in CDMO services.
Antibody CDMO—The "All-in-One Workshop" of Antibody Manufacturing
When an antibody drug transitions from concept to clinic, what concerns developers the most? Not a lack of creativity, but a loss of control in execution. Creative Biolabs' antibody CDMO solutions are designed to help overcome that bottleneck. It's an "all-in-one workshop" that takes you from DNA to cGMP, allowing you to keep antibody R&D from fragmented outsourcing. An expert from the company remarked at the event,
"We are seeing clients wanting more integrated and responsive systems from manufacturers. It's more than just producing contracts; it's about co-creation. We are trying to build safe and effective expressways for all innovative molecules."
Covering scales from 2 L to 2,000 L, supporting multiple formats (mAbs, BsAbs, ADCs), and allowing partners to complete all the developmental stages within one streamlined logical sequence are all aspects of integrated systems for co-creation.
Recombinant Antibody Engineering—Making Proteins Smarter
The recombinant antibody production and engineering module allows antibodies to be re-engineered like building blocks—whether humanized, fragmented, single domain, or bispecific, all variants are designed with biological precision.
During a talk, an expert stated, "Traditional recombinant production is just manufacturing. What we do is molecular craftsmanship, and we can predict which residues impact affinity and which mutations enhance stability. These 'fine-tunings' will improve the odds of success throughout the development process."
OmicsAb™ Platform—A High-Throughput Engine That Bends Time
The OmicsAb™ high-throughput antibody production platform was one of the most "time-defying" highlights at PEGS Europe. It breaks the limits of traditional 96-well expression systems and supports fully automated cloning, expression, and purification.
"Within days, we express and purify hundreds of candidate antibodies. This is a game-changer! Screening is no longer a slow process. It is a precision and efficiency race now." The OmicsAb platform works with different host systems, including CHO and HEK293, which allows biopharma developers to scale their cross-system biopharma testing. This versatility boosts the rapid early-stage decision-making, ultimately streamlining the system to meet the biopharmaceutical innovation pace.
"PEGS Europe is not just an exhibition—it's a mirror. It reflects the challenges of the industry while also revealing our own potential. Our mission is to make complex technologies controllable, reproducible, and scalable."
About Creative Biolabs
Creative Biolabs continues to focus on process development of bispecific antibodies, Fc-fusion proteins, and ADCs, along with the combination of AI-driven design and high-throughput screening to explore new frontiers in the manufacturing of next-gen biotherapeutics.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creativebiolabs.net/
Release ID: 89175926
Google
RSS